Abstract:To the Editor: Nowadays, imatinib and second generation tyrosine kinase inhibitors (2G-TKIs) as initial therapy are used in newly-diagnosed chronic myeloid leukemia (CML) present in the accelerated phase. However, rare data compared responses and outcomes between them. Data from 430 consecutive subjects with CML presenting in accelerated phase from 37 medical centers across China from May 2009 to March 2022 were interrogated. The diagnosis of accelerated phase and TKI-dose adjustment were based on European LeukemiaNet recommendations. Last follow-up was in September 2022. Transformation was defined as blood or bone marrow blasts ≥30% during TKI therapy. Transformation-free survival (TFS) was calculated as the interval from starting TKI-therapy to transformation, death, or censored at a transplant or last follow-up. Survival was calculated as the interval from starting TKI-therapy to death from any cause or censored at a transplant or last follow-up. Cumulative incidences of complete cytogenetic response (CCyR), major molecular response (MMR), and molecular response 4.5 (MR) were calculated using the Fine-Gray test considering competing events defined as switching to another TKI or therapy, transplant, or death. TFS and survival were calculated by the Kaplan–Meier method and compared by the logrank test, subjects were censored at switching to another TKI or therapy, a transplant, or the last follow-up. Propensity-score matching (PSM) was done to adjust for differences in baseline covariates between the cohorts including sex, age, splenomegaly on physical exam, comorbidity(ies) (based on Charlson Comorbidity Index), WBC counts, hemoglobin concentration, platelet concentration, percentages of blood and/or bone marrow blasts and blood basophils, high-risk additional chromosomal abnormality(ies) in Ph-chromosome positive cells between subjects receiving initial imatinib or a 2G-TKI and balance evaluated using the standardized absolute mean difference where score <0.02 was considered balanced. A 2-sided p < .05 was considered significant. SPSS 22.0 (SPSS, Chicago, IL) and R version 4.0.2 (R Core Team, Vienna, Austria) were used for analysis and graphing. Patients' characteristics were displayed in Table S1. At the last follow-up, 166 subjects in the imatinib cohort (62%) and 121 in the 2G-TKI cohort (74%) remained on their first TKI (p = .02). Hundred subjects (38%) initially receiving imatinib switched to nilotinib (n = 43), dasatinib (n = 46), ponatinib (n = 1), olverembatinib (n = 1), flumatinib (n = 6), chemotherapy (n = 3) because of therapy-failure (n = 82), adverse events (AEs, n = 7) or subject and/or physician's preference (n = 11). Forty three subjects (26%) receiving initial 2G-TKI switched to imatinib (n = 5), nilotinib (n = 3), dasatinib (n = 25), ponatinib (n = 3), olverembatinib (n = 3), interferon (n = 1) or flumatinib (n = 3) because of therapy failure (n = 31), AEs (n = 8) or cost (n = 4). Grade 3/4 haematologic AEs occurred in 38 subjects in the imatinib cohort (14%) and 42 in the 2G-TKI cohort (26%) during the first 3 months of TKI therapy (p = .03). Fifty four subjects in the imatinib cohort (20%) and 54 in the 2G-TKI cohort (33%) had a dose reduction and/or -discontinuation (p = .03). Among them, 73 (68%) were because of grade 3/4 thrombocytopenia (n = 46), leukopenia (n = 10), or both (n = 17); 28 (26%), non-haematologic toxicity. With a median follow-up of 39 (IQR, 18–73) months. 382 (90%) subjects achieved complete hematologic response (CHR) in 3 months. 5-year cumulative incidences of CCyR, MMR, and MR were 89% (95% Confidential Interval [CI], 85, 92%), 81% (76, 86%), and 53% (47, 59%). In the cohort of subjects with excess blasts, basophils ≥20%, platelet <100 10E+9/L and those with ≥2 of these co-variates 5-year cumulative incidences of CCyR were 79% (67, 92%), 95% (92, 99%), 78% (67, 89%), 69% (41, 98%, p-value for trend = .01), cumulative incidences of MMR, 75% (63, 88%), 85% (79, 91%), 74% (59, 90%), 74% (49, 99%, p-value for trend = .13) and cumulative incidences of MR, 56% (41, 72%), 56% (47, 64%), 47% (33, 62%), 34% (8, 61%, p-value for trend = .14). During follow-up 135 subjects (31%) failed ≥1 TKIs and 43 (10%) transformed to the blast phase. Twenty four subjects (6%) died of leukemia progression (n = 22) or other causes (n = 2). 5-year probabilities of TFS and survival were 88% (85, 91%) and 93% (90, 96%). In the cohort of subjects with excess blasts, basophils ≥20%, platelet <100 10E+9/L or ≥2 criteria, 5-year probabilities of TFS were 82% (72, 92%), 93% (90, 97%), 86% (78, 94%), 65% (37, 94%, p-value for trend = .01); survival, 92% (81, 100%), 95% (92, 98%), 93% (86, 99%), 74% (46, 100%, p-value for trend = .19). Results of uni-variable and multi-variable analyses were displayed in Tables S2–S7. In the total population and cohort with basophils >20% receiving 2G-TKI was associated with higher cumulative incidences of CCyR, MMR, and MR, whereas in the cohort with platelet <100 10E+9/L receiving 2G-TKI was associated with worse TFS. We did not analyze subjects with ≥2 criteria because of too few subjects. Received: 13 March 2023 Revised: 12 April 2023 Accepted: 18 April 2023

Assessment of Chronic Renal Injury in Patients with Chronic Myeloid Leukemia in the Chronic Phase Receiving Tyrosine Kinase Inhibitors

The Treatment of Patients with Chronic Myeloid Leukemia Chronic Phase Combined with Myelofibrosis with Tyrosine Kinase Inhibitors: A Chinese Population-Based Study.

Four-year Follow-Up of Patients with Imatinib-Resistant or Intolerant Chronic Myeloid Leukemia Receiving Dasatinib: Efficacy and Safety

[Hepatic Adverse Events Associated with Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia].

P684: a multicenter retrospective study in china: clinical characteristics and prognosis of patients with cml-cp treated with different tyrosine kinase inhibitors

Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Analysis of the Efficacy and Influencing Factors of Nilotinib or Dasatinib As Second- or Third-Line Treatment in Patients with Chronic Myeloid Leukemia in the Chronic Phase and Accelerated Phase

Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis

Chronic myeloid leukemia in renal transplantation patients in the era of tyrosine kinase inhibitors: A case report and review of the literature

Imatinib Compared with Second‐generation Tyrosine Kinase‐inhibitors in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group

Correlations Between Mutations in Cancer-Related Genes, Therapy Responses and Outcomes of the 3 Rd Generation Tyrosine Kinase-Inhibitor (TKI) in Persons with Chronic Myeloid Leukemia Failing Prior TKI-Therapy

Dasatinib Treatment Based on BCR-ABL Mutation Detection in Imatinib-Resistant Patients with Chronic Myeloid Leukemia

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

Superiority of Allogeneic Hematopoietic Stem Cell Transplantation to Nilotinib and Dasatinib for Adult Patients with Chronic Myelogenous Leukemia in the Accelerated Phase

A Multicenter Retrospective Chart Review Study of Treatment and Disease Patterns and Clinical Outcomes of Patients with Chronic-Phase Chronic Myeloid Leukemia in Third-Line Treatment or with T315I Mutation

Chronic Myelogenous Leukemia Patients with Highly Nilotinib-Resistant Bcr-Abl Mutations Demonstrate Similar Efficacy to Dasatinib, but Have A Higher Likelihood of Developing New Mutations in the Event of Clinical Resistance

[Comparison of Nilotinib Vs Imatinib As Frontline Therapy in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase].

Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study

Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis

[Severe Hematologic Toxicity and Its Impact on Treatment Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase-Inhibitor Therapy].